Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy
- PMID: 35440003
- PMCID: PMC9020080
- DOI: 10.1186/s13014-022-02052-z
Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy
Abstract
Background: Inherent resistance to radio/chemotherapy is one of the major reasons for early recurrence, treatment failure, and dismal prognosis of glioblastoma. Thus, the identification of resistance driving regulators as prognostic and/or predictive markers as well as potential vulnerabilities for combined modality treatment approaches is of pivotal importance.
Methods: We performed an integrative analysis of treatment resistance and DNA damage response regulator expression in a panel of human glioblastoma cell lines. mRNA expression levels of 38 DNA damage response regulators were analyzed by qRT-PCR. Inherent resistance to radiotherapy (single-shot and fractionated mode) and/or temozolomide treatment was assessed by clonogenic survival assays. Resistance scores were extracted by dimensionality reduction and subjected to correlation analyses with the mRNA expression data. Top-hit candidates with positive correlation coefficients were validated by pharmacological inhibition in clonogenic survival assays and DNA repair analyses via residual γH2AX/53BP1-foci staining.
Results: Inherent resistance to single-shot and similarly also to fractionated radiotherapy showed strong positive correlations with mRNA expression levels of known vulnerabilities of GBM, including PARP1, NBN, and BLM, as well as ATR and LIG4-two so far underestimated targets. Inhibition of ATR by AZD-6738 resulted in robust and dose-dependent radiosensitization of glioblastoma cells, whereas LIG4 inhibition by L189 had no noticeable impact. Resistance against temozolomide showed strong positive correlation with mRNA expression levels of MGMT as to be expected. Interestingly, it also correlated with mRNA expression levels of ATM, suggesting a potential role of ATM in the context of temozolomide resistance in glioblastoma cells. ATM inhibition exhibited slight sensitization effects towards temozolomide treatment in MGMT low expressing glioblastoma cells, thus encouraging further characterization.
Conclusions: Here, we describe a systematic approach integrating clonogenic survival data with mRNA expression data of DNA damage response regulators in human glioblastoma cell lines to identify markers of inherent therapy resistance and potential vulnerabilities for targeted sensitization. Our results provide proof-of-concept for the feasibility of this approach, including its limitations. We consider this strategy to be adaptable to other cancer entities as well as other molecular data qualities, and its upscaling potential in terms of model systems and observational data levels deserves further investigation.
Keywords: ATM; ATR; Chemosensitization; Clonogenic survival; Correlation analysis; DNA damage response; Glioblastoma; LIG4; Radiosensitization; Radiotherapy; Temozolomide; Therapy resistance.
© 2022. The Author(s).
Conflict of interest statement
All authors declare that there is no conflict of interest.
Figures




Similar articles
-
Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data.Radiat Oncol. 2023 Mar 11;18(1):51. doi: 10.1186/s13014-023-02241-4. Radiat Oncol. 2023. PMID: 36906590 Free PMC article.
-
ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.Oncotarget. 2024 Jan 16;15:1-18. doi: 10.18632/oncotarget.28551. Oncotarget. 2024. PMID: 38227740 Free PMC article.
-
ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.J Neurooncol. 2018 Jul;138(3):479-486. doi: 10.1007/s11060-018-2819-3. Epub 2018 Mar 8. J Neurooncol. 2018. PMID: 29520610
-
Treatment considerations for MGMT-unmethylated glioblastoma.Curr Neurol Neurosci Rep. 2015 Jan;15(1):507. doi: 10.1007/s11910-014-0507-z. Curr Neurol Neurosci Rep. 2015. PMID: 25394859 Review.
-
DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.Mol Oncol. 2022 Jan;16(1):11-41. doi: 10.1002/1878-0261.13020. Epub 2021 Jun 11. Mol Oncol. 2022. PMID: 34036721 Free PMC article. Review.
Cited by
-
Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data.Radiat Oncol. 2023 Mar 11;18(1):51. doi: 10.1186/s13014-023-02241-4. Radiat Oncol. 2023. PMID: 36906590 Free PMC article.
-
Identification and validation of a prognostic risk model based on radiosensitivity-related genes in nasopharyngeal carcinoma.Transl Oncol. 2025 Feb;52:102243. doi: 10.1016/j.tranon.2024.102243. Epub 2024 Dec 15. Transl Oncol. 2025. PMID: 39675252 Free PMC article.
-
Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.Acta Neuropathol Commun. 2025 Jun 5;13(1):126. doi: 10.1186/s40478-025-02046-4. Acta Neuropathol Commun. 2025. PMID: 40468460 Free PMC article. Review.
-
Polyoxometalate Nanoparticles as a Potential Glioblastoma Therapeutic via Lipid-Mediated Cell Death.Int J Mol Sci. 2022 Jul 27;23(15):8263. doi: 10.3390/ijms23158263. Int J Mol Sci. 2022. PMID: 35897839 Free PMC article.
-
Proton pump inhibitors display anti-tumour potential in glioma.Cell Prolif. 2023 Jul;56(7):e13321. doi: 10.1111/cpr.13321. Epub 2022 Aug 12. Cell Prolif. 2023. PMID: 35961680 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
- INST 409/126-1 FUGG/Deutsche Forschungsgemeinschaft
- INST 409/126-1 FUGG/Deutsche Forschungsgemeinschaft
- 02NUK047C BMBF ZISStrans/Bundesministerium für Bildung und Forschung
- 02NUK047C BMBF ZISStrans/Bundesministerium für Bildung und Forschung
- FoeFoLe program of the Medical Faculty/Ludwig-Maximilians-Universität München
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous